Biotinyl analogues of amylin as biologically active probes for amylin/CGRP receptor recognition  by Chantry, Andrew et al.
Volume 296, number 2, 123-127 FEBS 10572 
© 1992 Federation of European Biochemical Societies 00145793/9~$5.00 
January 1992 
Biotinyl analogues of amylin as biologically active probes for amylin/ 
CGRP receptor recognition 
Andrew Chantry  ~*, Elizabeth A. Foot  2, Brendan Leighton -~, Anthony  J. Day t and Antony  C. Willis t 
~ MRC lmmunochemistry Unit. Departntent of Biochemistry. and ~'Departntent of Biochemistry, Utliversity of Oxford, South Parks 
Road, Oxford, OXI 3QU, UK 
Received ! November 1991 
Biotinyl analogues of rat amylin were synthesised with sulfosu~inimidyl 2-(biotinamido) ethyl-1,3-dithiopropionate (N HS-SS-Biotin). Biotinylated 
amylin peptides were purified by HIaLC, quantltated, and the presence of the biotin group at Lys-I confirmed by peroxidase-labelled avidin and 
FAB mass spectroscopy. Amylin.biotin retained a similar affinity for binding to rat liver plasma membranes ¢.ompared with rat atnylin and also 
completely inhibited insulin-stimulated glycogen synthesis n rat soleus muscle incubated invitro. These biologically active amylln probes will enable 
a complete analysis of anaylin/CGRP receptor er, pression in various cell types and facilitate the isolation and characterisation f the hormone- 
receptor complex. 
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1. INTRODUCTION 
Amylin is a 37,amino acid polypeptide which shares 
about 50% primary amino acid sequence identity with 
calcitonin gene-related peptide [1]. Amylin, which was 
originally isolated from the amyloid mass in the pancre- 
ases of type 2 diabetics, has all the hallmarks of a novel 
glucoregulatory hormone which counteracts insulin ac- 
tion [2,3]. Interestingly, the neuropeptide CGRP is now 
known to have a high degree of functional, as well as 
structural, similarity with amylin. Both amylin and 
CORP are affective inhibitors of insulin-stimulated gly- 
cogen synthesis in skeletal muscle incubated in vitro [4] 
and amylin also counter-regulates the effect of insulin 
on hepatic glucose production in vivo [5]. 
Receptors for CGRP have been identified on a num- 
ber of cell lines and tissues which are often of vascular 
origin, consistent with the role of CGRP as a potent 
vasodilator [6]. High affinity CGRP receptors have also 
been localized to the major sites of  glucose metabolism, 
the liver [7,8] and skeletal muscle [8,9]. Recently, we 
have shown that amylin and CGRP cross-react with the 
~:~l-labeiled CGRP binding site in both liver and skele- 
tal muscle, based both on equilibrium binding analysis 
and covalent cross-liking techniques [8]. Therefore, it is 
becoming increasingly apparent that any explanation of 
the combined physiology of amylin and CGRP must 
encompass differential ocalization of these peptides 
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and/or the presence of" receptor sub-types distributed on 
specific target issues. 
An important pre-requisite for the analysis of puta- 
tive receptor sub.types are labelled peptides which 
retain receptor recognition activity. Iodination of 
human CGRP on the His-10 residue does not appear to 
reduce its receptor binding capacity. No biologically 
active :-Sl- labelled amylin is available and, at least in 
our hands, iodination of amylin on either Tyr-37 or 
Lys-I substantially reduced its binding affinity [8]. The 
introduction of the biotin moiety via the primary amine 
groups on amylin could provide useful functional 
ligands for the study of amylin/CGRP receptor expres- 
sion and the distribution of receptor sub-types in vari- 
ous cells or tissues, and also facilitate the isolation of the 
amylin- and/or CGRP-receptor complex(as). Here, we 
investigated the relative binding of biotinylated 
analogues of rat amylin to rat liver plasma membranes 
and also demonstrate he retention of biological activity 
of these derivatives, based on their ability to inhibit 
insulin-stimulated glycogen synthesis in rat muscle in 
vitro. 
2. MATERIALS AND METHODS 
2.1 Materials 
Synthetic rat amylin (Camebridge Research Biaehemieals. IdK) was 
dissolved in 3 mM HCI. aliquoted, and stored at -20"C until u~l .  
t:Sl-labelled human CGRP-I (ca. 2000 el/retool) was obtained from 
Amersham, UK. Sull'osaeeinimidyl 2-(biotinamido) ethyl-l,3-dithio- 
propionate fNl-IS-SS-Biotin) and N-su~¢inimidyl-3(4-hydroxyphenyl) 
propionate (Bolton-Hunter reagent; SHPP) were from Pierce Chemi- 
cal Co., UK. Peroxida~e-labelled avidin was from Sign~a. 
2.2. Synthesis attd isolat{on of biotittylated peptides 
gyathe.sis of biotinylat~--d peptides was ~.,~rf, o,,-~ ,,:F '~ . . . . .  ,,,,~,,,g"- 59/~.'1 
(1 myml) of rat amylin in 3 mM HCI with 100,ul (0.4 mg/ml) NHS- 
SS.Biotin or SHPP in 0.1 M sodium borate, pH 7.5. After 30 rain, I00 
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fll 0.1% trifluoroacetic acid was added, reaction mixtures were cen- 
trifuged (10 000 × g; 10 mln) and then immediately fractionated by 
high-performance liquid chromatography (HPLC). 
Samples were applied to a Whatman Partlsil-10 ODS-3 column (250 
x 4.6 ram) and eluted with a gradient of 5-90% with O. 1% trifluoroace- 
tic acid in water (solvent system A) and 0.09% trifluoroacgtic acid, 
80% aeetonitrile inwater (solvent system B) at a flow rate of I ml/min. 
Main proteinaceous peaks as determined by absorbattce at215 nM 
were aliquoted, dried with a centrifugal evaporator and stored esicca- 
ted under argon at -20°C. 
2.3. Dot.blot assay 
Dried peptides were resuspended in 3 mM HCI and 3 pl aliquots of 
200, 67 and 22 p~/ml solutions applied to nitro~llulose. Blots were 
then incubated with 1% bovine serum albumin in phosphate buffered 
saline (PBS) for 1 h at room temperature toblock non-specific binding 
sites and then with peroxidase.labelled avidin (2Fg/ml) for 1 h at room 
temperature, Alter washing extensively with PBS, blotfi were devel- 
oped with i mg/ml diaminobcnzldined0.02% hydrogen peroxide in 
PBS. 
2.4. F..I B mass spectrotnetry 
Electrospray mass spectra were measured on a YG BIO Q triple 
quadruple atmospheric preszure mass spectrometer equipped with an 
electrospray interfere (VG Bioteeh, Tudor Road, Altrineham, 
Cheshire). Samples (10 pl) were injected into an electrospray source 
via a loop injector (Rheodyn¢ 5717) as a solution, typically 25-50 
pmol//al, in water/methanol (1:1) containing 1% acetic acid at a flow 
rate of 2 ~1 per mln (Applied Biosystems model 140A dual syrin8 e
pump). The mass spectrometer was scanned over the mass range 
700-1500 Da. The instrument was calibrated with myoBlobin (20 
pmol//.,,l, reel. wt. 16951.5 Da). 
2.5. Receptor binding attd soleus muscle assays 
The methodology for the rat liver plasma membrane binding assay 
has been described previously [8]. ~l-labelled human CGRP-I was 
used as a radiolabelled tracer (25 pM) and receptor recognition activ- 
ity of peptides and biotinylated analogues assessed by their ability to 
compete for J:sI-CGRP binding. The rat soleus muscle assay has been 
described previously [4]. Concentrations of all unlabelled peptides 
were accurately determined inall e~periments by amino acid analysis 
using a Waters Pico Tag system ll0]. 
3. RESULTS 
In rat amylin there are 2 iodinatable residues, Lys-1 
(or-amino and t -amino groups) at the N-terminal  and 
also the C-terminally amidated Tyr-37. Tyr-37 amida- 
tion is known to be important for biological activity [l l] 
and, therefore, interfering with this region of the mole- 
cule will affect receptor binding activity. Introduction 
o f  l'~sI into the 2 pr imary amine groups on the N-termi-  
nal Lys via the Bolton-Hunter eagent, produced a ra- 
diolabelled peptide which failed to specifically bind to 
rat liver plasma membranes [8]. The reagent used in the 
iodination study has a short spacer length, and the 
affect on receptor binding activity may be due to steric 
hindrance. We therefore chose to derivatize the Lys-I  
group with NHS-SS-Biot in which has a longer spacer 
and would introduce the versatile biotin label with the 
additional advantage of a thiol-cleavable group. 
Fract ionation by HPLC of  rat amylin after reacting 
with NHS-SS-Biotin yielded 1 major peak A.2 and a 
minor  peak A.1 (Fig. 1). When the reaction is per- 
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Fig. 1. Isolation of biotinylated analogues of rat amylin by HPLC. 
Biotinylated rat amylin was separated on a Partisil. 10 ODS-3 (250×4,6 
ram) with a gradient of 5-90% with 0.1% trifluroacetic acid in water 
and 0.09% trifluroacetic acid, 80% acetonitrile inwater at a flow rate 
oi l  ml/min. The major b/otinylated products are indicated (A.I and 
A.2) and the migration of synthetic rat amylin (A) is shown by the 
dotted line. The major peak at about 40% acetonitrilc isderived fl'om 
the reagent Nl-lS-SS-blotin. (Insert) Detection of biotinylated peptides 
by dot blot assay and avldin-labell~ peroxidase. 
formed at pH 7.0, instead of pH 7.5, the relative level 
of  protonat ion o f  the oz. and e-amino groups is reduced, 
consequently the amount  of  peak A.I relative to peak 
A.2 was substantially increased (data not shown). The 
likely explanation for this is that the more hydrophobic 
peak A,2 represents amylin with 2 attached biotin moie- 
ties, The presence of the biotin group in both peaks was 
confirmed by qualitative dot-blot analysis (Fig. 1, in- 
sert), 
By FAB mass spectrometry, rat amylin (peak A) mi- 
grates as a main peak with a reel. wt. of  3920.1 Da 
which is in very good agreement with the predicted 
value of  3920.5 Da (Fig. 2). Peaks B and C in Fig. 1 
represent peptide with bound sodium and potassium 
ions, respectively, and Peak D is an unknown contam- 
inant. The hiotinylated peptides (peak AI and A2) 
migrate as major  species with mol. wts. of  4309.4 and 
4699.25 Da, respectively (Fig. 2). The calculated mol. 
wt. of an attached biotin moiety is 390.1 Da, therefore, 
peak A1 represents amylin with a single biotin and peak 
A2 is amylin with 2 attached biotins. 
The binding affinities of  amylin relative to the bioti- 
nylated analogues isolated by HPLC as shown in Fig. 
1 were examined by equil ibrium binding analysis. We 
have shown previously that both amylin and CGRP can 
compete for ~25I-CGRP binding to rat liver plasma 
membranes [8]. Derived lC~0 values for the ~251-CGRP 
displacement from rat liver plasma membranes by amy- 
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Fig. 2. FAB mass spectroscopy ofanaylin and amilyn-biotin derivatives A, A.I and A.2 described in Fig. I. 
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lin and amylin-biotin are summarized in Table I. In 
these experiments, rat amylin gave an IC~0 of 2.5 × 10 -s 
M, and both biotinylated analogues, peaks A, 1 and A.2, 
gave only marginally higher IC~o values of  3.2 × 10 -s M 
and 4.0 × 10 -a M, respectively. 
Biotinylated analogues of  rat amylin were also tested 
for their ability to elicit a biological response. For this 
measurement we monitored the effects of  amylin and 
di-biotin-amylin (peak A.2) on insulin-stimulated rates 
of  glycogen synthesis and lactate formation in isolated 
incubated rat soleus muscle preparations (Table 1). So- 
leus muscles were pre-incubated for 30 min in the pres- 
ence of insulin (100/~U/ml) and [U-laC]ghtcose. After 
30 s in  some muscles were removed and these served as 
the control 1 values (Table 1). Other muscles were incu- 
bated for a further 30 s in ,  either with insulin and ~4C- 
labelled glucose alone (control 2) - to obtain steady 
state values for stimulation of  glucose metabol ism in the 
isolated incubated soleus muscle preparations, or in ad- 
dition with 100 nM underivatised/biotinylated amylin 
peptides (see Table I). Both rat amylin and di-biotin- 
amylin completely inhibited the stimulation o f  glycogen 
synthesis by insulin over the last 30 min of the incuba- 
tion. Amylin and CGRP are known to increase the rates 
of  glycogenolysis, and hence increase the rate of  lactate 
formation in this system [3]. In the present study, there 
were equivalent increases in the rates o f  lactate forma- 
Table i 
Biological activity of amylin and biotin-amylin 
Additions Rates ~mol/g wet wt./unit ime) 
Glycogen synthesis Lactate formation 
zr 
Control 1 = 2.20+0.31 - 6.81±0.33 - 
Control 2 h 5.04_+0.41 2.84_+0.41 13.21 +__0.77 6.40+_0.77 
Amylin b 2.31+__0.28' 0.11"+0.28" 16.49±0.80" 9.68-+0.80" 
Di.biotin- 2.85"+0.17' 0.65+0.17" 16.70-+1.47" 9.89"+1.47' 
amylin b
Results are presented as means _ SEM. Mono-biotin amylin was not 
tested. 
= Muscles were pre-incubated for 30 sin with insulin (100,uU/ml) and 
[UJ+C]glucose (0.4/~Ci/ml). 
b Musclcs were incubated for a further 30 mln either in tile presence 
of insulin and ~+C.tabelled glucose only (Control 2), or in addition 
with 100 nM amylin or di-biotinylated amylin. 
= A is tile response of glycogen synthesis to insulin over the last 30 sin 
of  the incubation. 
dd is the response of lactate formation to insulin over the last 30 sin 
or tile incubation period. Statistically significant differen~"~ (non- 
paired Student's t-test) from Control 2 values are indicated by " 
(P<O.05). 
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tion by amylin and the di.biotin-amylin, which suggests 
that there is an increase in the rate of glycogenolysis. 
4. DISCUSSION 
The present study demonstrates for the first time a 
labelled amylin analogue which can be adequately and 
routinely detected and retains both biological and re- 
ceptor binding activity (Table I). The introduction of 
the biotin moiety at the N-terminal Lys residue provides 
a probe for the study of amylin receptor expression in 
various cell types and will enable isolation and charac- 
terization of amylin receptors. Recently, it has been 
reported that t'~5I-amylin labelled with the BoRon- 
Hunter reagent can be used to identify high affinity 
amylin binding sites in hepatic non-parenchymal cells 
[! 2]. However in our studies using rat liver plasma mem- 
branes, in which we have shown both here and previ- 
ously [8] that unmodified rat amylin is a binding-com- 
petent ligand, we find that amylin labelled with non- 
iodinated Bolton-Hunter reagent has a reduced (5-10- 
fold) receptor binding activity (A. Chantry, unpub- 
lished), 
Amylin labelled at Lys-1 with BoRon-Hunter reagent 
may retain sufficient binding affinity for preliminary 
analysis of amylin receptor expression i  some systems. 
However, it seems likely that an optimal spacer length 
between the peptide and the bulk of the attached eriv- 
ative is required to fully prevent steric hindrance of 
receptor-ligand interactions. In this regard we have 
found that the N-terminal region of amylin and CGRP 
plays a role in receptor binding since reduction of the 
2-7 disulphide bridge abolishes receptor recognition (C. 
Bacon and A. Chantry, unpublished observations) and 
biological activity [11]. The biotinylated analogues de-" 
scribed here have a spacer with a disulphide bridge and 
8 atoms between the biotinyl carboxyl group and the 
N.terminal Lys. However, the BoRon-Hunter derivative 
has only 2 atoms and is presumably not flexible enough 
or of sufficient length to avoid impinging on the ad- 
jacent N-terminal residues of amylin. One solution 
therefore might be to introduce an iodinatable Boiton- 
Hunter reagent with a longer spacer arm. 
In addition to the use of biotinylated ligands for the 
analysis of receptor expression, the very high affinity of 
biotin for egg white avidin and bacterial streptavidin 
(Ka "-" 10 -~ M [13]) permits the use of these biotinylated 
ligands as probes for isolating and localizing their corre- 
sponding cell-surface receptors. The success of this ap- 
proach is critically dependent upon the ability of the 
biotinyl-substituted hormone ligand to bind simultane- 
ously to both avidin and the receptor. For example, the 
hydro-osmotic a tivity of biotinylated analogues of va- 
sotocin was reversed following the addition of avidin 
[14]. However, the spacer arms of the molecules used in 
this study were very short. The length of the spacer arm 
in amylin-SS-Biotin is significantly greater and, assum- 
ing these chains to be fully extended, it is very unlikely 
that the avidin-biotin interaction would interfere with 
the formation of the receptor-ligand-Biotin-avidin 
complex. Indeed, we have recently optimized conditions 
for using biotinylated amylin to specifically remove and 
isolate amylin/CGRP receptors from detergent solubil- 
ized liver plasma membranes u ing avidin-agarose chro- 
matography in a single step procedure [15]. We have 
shown previously that binding of ~2~I-CGRP to rat liver 
plasma membranes i  reversed by the addition of an 
excess of unlabelled amylin and CGRP [8]. Therefore, 
the same conditions can be used to specifically elute 
amylin/CGRP receptors from agarose-avidin-Bio- 
tin-SS-ligand-receptor c mplexes. The slightly reduced 
receptor affinities of the biotinylated analogues (1-2- 
fold lower) are still high enough to maintain the re- 
ceptor-ligand interaction but, at the same time, will 
facilitate the reverse binding process in the presence of 
excess unlabelled ligand with a higher affinity than the 
corresponding biotinylated erivative. The presence of 
the thiol-cleavable disulphide bridge within the bioti- 
nylatcd derivatives also provides alternative receptor 
elution conditions. The biotinylated analogues de- 
scribed here may also be used to directly obtain the 
amylin/CGRP receptor eDNA sequence by screening 
transfected COS cells transiently expressing rat liver 
eDNA [i 6]. 
The combined physiology of amylin and CGRP has 
been extensively studied in recent years and a great deal 
of confusion has arisen over the site of action, func- 
tional overlap and relative contributions of these pep- 
tides to normal metabolic processes. The biologically 
active biotinylated amylin analogues described in this 
study will help to resolve many of the current incon- 
sistencies. 
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